Joseph A Osborne

US Patent:

20100209343, Aug 19, 2010

Filed:

Feb 17, 2010

Appl. No.:

12/658881

Inventors:

Neil Bander - Chappaqua NY, US
Joseph Osborne - New York NY, US
Stanley J. Goldsmith - Floral Park NY, US
Shankar Vallabhajosula - Larchmont NY, US

Assignee:

Cornell Research Foundation, Inc. - Ithaca NY

International Classification:

A61K 51/10
A61K 49/06
A61K 49/14
G01N 33/53
A61P 35/00

US Classification:

424 149, 424 934, 424 94, 435 71

Abstract:

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

US Patent:

20220323618, Oct 13, 2022

Filed:

Jan 19, 2022

Appl. No.:

17/579470

Inventors:

- Ithaca NY, US
Joseph Osborne - New York NY, US
Stanley Goldsmith - Floral Park NY, US
Shankar Vallabhajosula - Larchmont NY, US

International Classification:

A61K 51/10
A61K 51/04

Abstract:

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

US Patent:

20200282085, Sep 10, 2020

Filed:

Oct 15, 2019

Appl. No.:

16/653655

Inventors:

- ITHACA NY, US
Joseph Osborne - New York NY, US
Stanley Goldsmith - Floral Park NY, US
Shankar Vallabhajosula - Larchmont NY, US

International Classification:

A61K 51/10
A61K 51/04

Abstract:

A method for identifying a patient for cancer therapy can include administering a diagnostic dose of a detectably labeled first binding agent to a patient, the detectably labeled binding agent being capable of binding a molecular target. The method also includes selecting a patient for administration of a therapeutic dose of a second binding agent capable of binding a cellular target, wherein the selected patient exhibits a positive reading for the detectably labeled first binding agent. Furthermore, the method can include administering a therapeutic dose of the second binding agent to the patient.

US Patent:

20180133350, May 17, 2018

Filed:

May 19, 2016

Appl. No.:

15/576119

Inventors:

- New York NY, US
Sarah M. Cheal - New York NY, US
Steven M. Larson - New York NY, US
Joseph Reginald Osborne - New York NY, US
Edward Komin Fung - New York NY, US
David Ulmert - New York NY, US

International Classification:

A61K 51/10
G16H 50/50

Abstract:

The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.